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A b s t r A c t
bAckground: Saccharomyces boulardii prevents antibiotic-induced diarrhea and ex-
erts anti-H.pylori effects in vitro and in vivo. 
Aim: To assess whether S. boulardii enhances the efficacy of classic triple therapy in 
eradicating H. pylori. 
methods: Seventy patients with peptic ulcer or functional dyspepsia according to 
Rome III criteria and H. pylori infection were treated with omeprazole 20 mg bid, 
clarithromycin 500 mg bid and amoxicillin 1 g bid for 14 days. A total of 36 out of 70 
(51%) patients were randomized to S. boulardii [Ultralevure®, two capsules tid for 14 
days (group A) and 34 (49%) on no intervention (group B). H. pylori eradication was 
assessed by a 13C-Urea Breath Test. 
results: At baseline there were no significant differences between the two groups 
in any patient or disease characteristics. H. pylori was eradicated in 30/36 (83.4%) 
patients in group A vs 20/34 (58.8%) in group B (P=0.034, 95% CI 4.4% to 43.6%). 
Seven patients in group B (20.6%) and 1 patient in group A stopped treatment because 
of diarrhea (95% CI 3.3% to 32.7%, P=0.026). Multi-factorial analysis did not reveal 
any patient or disease related parameter linked to treatment outcome except for the 
use of the probiotic. 
conclusion: S. boulardii enhanced the effect of classic triple therapy mainly by pre-
venting antibiotic- and/or proton pump inhibitor-induced diarrhea.
i n t r o d u c t i o n 
Helicobacter pylori (H. pylori) infection affects 70-90% of the population in devel-
oping countries and 25–50% in developed countries.1 In the majority of the cases H. 
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pylori induces a life-long mild chronic superficial antral gas-
tritis which may be asymptomatic and causes no harm to the 
affected individuals. Less often, however, the infection may 
initiate a sequence of events leading onto the development 
of peptic ulcer disease, gastric adenocarcinoma, mucosa-
associated lymphoid tissue (MALT) B-cell lymphoma and/or 
extra-gastric diseases.2-5 Since we lack data on risk factors for 
predicting unequivocally who of the infected individuals will 
develop H. pylori-related diseases, it has been recommended 
that the infection be cured in all patients.2,3 
A proton-pump inhibitor (PPI) with amoxicillin and 
clarithromycin (classic triple therapy, CTT) is still the treat-
ment of choice for eradication of H. pylori infection and is now 
recommended for 10-14 days.2 However, the efficacy of CTT 
is compromised by increasing resistance to clarithromycin 
and poor adherence.6 The latter is largely due to the number 
of consumed tablets, duration of treatment, and treatment-
related adverse events, predominantly gastrointestinal, such 
as nausea, bloating, epigastric pain, vomiting, and diarrhea.7 
Discontinuation of treatment reduces eradication rates of H 
pylori and increases further resistance to antibiotics. Thus, CTT 
cannot usually achieve eradication rates greater than 80%, 
a figure that is considerably lower for patients who harbor 
clarithromycin-resistant H. pylori strains.
The most worrisome adverse event, diarrhea, is related to 
both antibiotics and PPIs and is usually due to quantitative 
and qualitative alterations in the gut microbiota including the 
development of Clostridium difficile infection.8 Thus, at least 
in theory, some probiotics could enhance the efficacy of CTT 
by a dual mechanism, improving adherence (by preventing 
diarrhea) and exerting a synergistic effect to antibiotics (by a 
direct anti-H. pylori action). Probiotics are ‘live microorganisms 
which when administered in adequate amounts confer a health 
benefit on the host.9 Various probiotics have been documented 
to exert anti-H. pylori effects both in vitro10,11 and in vivo.12-21 
Saccharomyces boulardii probiotics have shown efficacy in sev-
eral types of acute diarrhea22 and may also induce morphologic 
changes in H. pylori cell lines consistent with cellular damage23 
and reduce by 12% H. pylori colonization of infected children.24 
Thus, the aim of this study was to investigate the efficacy of 
a widely available, single strain of S. boulardii preparation as 
an adjunct to CTT.
P A t i e n t s  A n d  m e t h o d s
PA t i e n t s
This was a prospective, randomized, controlled, single-
center study conducted in the first Department of Gastroenter-
ology, at Evagelismos Hospital, Athens, Greece, which recruited 
consecutive patients aged 18-75 years with H. pylori-related 
peptic ulcer disease or functional dyspepsia according to Rome 
III criteria during a 3-year period (January 1, 2005 – December 
31, 2007). Rome III criteria include one or more of the follow-
ing symptoms of at least 3-month duration, with onset at least 
6 months previously: bothersome postprandial fullness, early 
satiation, epigastric pain, epigastric burning and no evidence 
of structural disease (including upper endoscopy) that is likely 
to explain the symptoms. Exclusion criteria were age under 
18 years, prior treatment with clarithromycin, treatment with 
other antibiotics and/or PPIs in the last 3 months prior to 
inclusion, chronic treatment with aspirin and/or non-steroidal 
anti-inflammatory drugs (NSAID), gastro-esophageal reflux 
disease (GERD), cholelithiasis, current or intended pregnancy, 
chronic heart, pulmonary, hepatic, or renal failure, malignancy, 
and inability to comply with the terms of the study protocol.
s t u d y  P r o t o c o l
Consecutive dyspeptic patients who consented to partici-
pate in this study underwent detailed physical examination, 
laboratory tests (full blood count, erythrocyte sedimentation 
rate, C-reacting protein, routine liver function tests, blood-urea 
nitrogen, blood glucose, serum creatinine, and urinalysis), 
abdominal ultrasound, and esophago-gastro-duodenoscopy. 
The presence of H. pylori was sought by a rapid urease test 
(CLO-test, Delta West Ltd, Bentley, Australia) on fresh biopsy 
specimens from the antrum and by histology (modified Giemsa 
staining) on 10% formalin fixed paraffin embedded mucosal 
biopsies obtained from uninvolved areas of the gastric antrum 
and the body. Gastritis activity and severity were scored ac-
cording to the Houston updated Sidney classification.25 Patients 
were considered infected when both the CLO-test and histology 
confirmed the presence of H. pylori. 
H. pylori infected patients were randomized to two treat-
ment groups as follows: Group A included patients who 
received omeprazole (20 mg twice daily, one hour before 
meals), clarithromycin (500 mg twice daily with meals), and 
amoxicillin (1 g, twice daily with meals) for 14 days (OAC-14) 
plus a S. boulardii preparation [Ultra Levure® capsules, two 
capsules three times a day; 1 capsule contains 50mg (x106 live 
microorganisms) S. boulardii strains in lyophilized form]. Group 
B patients received OAC-14 only. Group B did not include a 
S. boulardii placebo preparation. In addition, patients in each 
group were unaware that there was another treatment arm in 
the study employing a different therapeutic regimen.
Cure of H. pylori infection was considered when a com-
mercially available 13C-Urea Breath Test [13C-UBT, INFAI-
test (Institut Für biomedizinische Analytik & NMR-Imaging), 
Bochum, Germany] at 6 weeks post treatment was negative 
in patients who had discontinued PPIs, probiotics and/or 
antibiotics. 
A single non-blinded physician (AR) randomized patients, 
allocated prescriptions, reviewed patients notes and arranged 
the appointments for the 13C-UBT tests. Patients used note 
books to record proper intake of prescribed medication and 
any adverse event that developed during the course of treat-
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intervals (95% CI) were calculated for H. pylori eradication 
and adverse events to treatment. P values lower than 0.05 were 
considered significant. Multiple logistic regression analysis 
was performed to evaluate the potential risk factors for the 
outcome of treatment, including age, gender, smoking (yes/
no), peptic ulcer disease (yes/no) functional dyspepsia (yes/
no), gastritis score (severity and activity) in the antrum and 
the corpus of the stomach, social drinking (yes/no), body mass 
index (normal/abnormal), and treatment (combined OAC-14 
with S. boulardii versus OAC-14). The study was approved by 
the Institution Review Board of the Evagelismos Hospital. All 
patients gave written informed consent.
r e s u l t s
Between January 1, 2005 and December 31, 2007, 125 
H. pylori infected patients were evaluated for inclusion in 
this study but finally only seventy patients who fulfilled the 
inclusion criteria and consented to participate were enrolled. 
Patient demographic and clinical data are given in Table 1. 
Notably, patients with peptic ulcer disease and/or functional 
dyspepsia were more or less equally distributed in the two 
treatment groups (P=0.47). A flow-chart of the study protocol 
is outlined in Figure 1.
Overall, 33 of 36 (91.7%) patients completed the study in 
group A versus 27 of 34 (79.4%) patients in group B (P=0.182) 
(Figure 1). Considering patients who did not complete the study 
as ‘treatment failures’, H. pylori infection was eradicated in 30 of 
ment. In order to ascertain the highest possible adherence to 
treatment, all enrolled patients were given oral and written 
instructions concerning proper intake of treatment and free-
access to mobile telephone of the physician who was responsible 
for the randomization (AR). All other study personnel were 
unaware of patient data and treatment category. 
s t A t i s t i c A l  A n A ly s i s
In calculating the sample size it was estimated that 34 
patients per group should be studied to detect a 20% differ-
ence in eradication rates with 80% probability (two-sided 
test; a=0.01) assuming a 65% eradication rate after OAC-14 
therapy which is the median successful eradication rate in our 
department using the classical triple therapy for 14 days. The 
primary end-point of this study was the eradication of H. pylori. 
Secondary end-points were the influence of patient clinical and 
demographic parameters on eradication rates of H. pylori and 
the rate of adverse events overall and diarrhea in particular. 
Results were analyzed both by the intention-to-treat (ITT) 
and per protocol (PP) methods. All patients that received at 
least one of the study medications were included in the ITT 
analysis; patients who for whatever reason did not complete 
the 14-day therapy or did not return for re-evaluation after 
treatment were considered as treatment failures. Only patients 
who completed the treatment and underwent successfully 
UB testing 6 weeks post treatment were included in the PP 
analysis. Comparisons between the two treatment groups were 
performed using the Mann-Whitney U-test and the Fisher’s 
exact test where appropriate. Exact binomial 95% confidence 
tAble 1. Patient demographic and clinical characteristics
Patients
oAc-14 plus S. boulardii
(group A)
oAc-14 alone
(group b) P
n 36 34 n.s.
Gender (male/female) 19/17 19/15 n.s.
Age (years)  
median (range) 47 (18-72) 45 (19-70) n.s.
Disease duration (years) 
Median (range) 12 (0.2-27) 14 (0.2-29) n.s.
Smokers (n, %) 20 (56%) 21 (62%) n.s.
Social drinkers (n, %) 12 (33%) 12 (35%) n.s.
Body mass Index (BMI) 
median (range) 29 (25-33) 30 (23-32) n.s.
Cause of dyspepsia 
Peptic ulcer disease (n, %) 
Functional (n, %)
15 (42%)
21 (58%)
11 (32%)
23 (68%)
n.s.
n.s.
OAC-14, classical anti-Helicobacter pylori triple therapy consisting of Omeprazole, Amoxicillin, and Clarithromycin for 14 days. n.s.: not significant.
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36 (83.4%) patients in group A and in 20 of 34 (58.8%) in group 
B (ITT analysis, P=0.034, 95% CI 4.4% to 43.6%) (Table 2). 
The absolute gain in eradication rates by the combined OAC-14 
and S. boulardii therapy over OAC-14 alone was 24.6%. By PP 
analysis, eradication rates were 90.9% in group A and 74% in 
group B, respectively (95% CI -43.76% to 77.76%, P=0.097) 
(Figure 1) (Table 2). Multi-factorial analysis did not reveal 
any other patient demographic, clinical, endoscopic and/or 
histologic parameter related to the effectiveness of treatment 
except for the use of S. boulardii. 
Treatment was better tolerated in group A: two patients 
with peptic ulcer disease were withdrawn voluntarily after they 
had completed 10 days of treatment because they felt well and 
only one patent (2.8%) was withdrawn for adverse events (diar-
rhea) (Table 2). In contrast, seven patients were withdrawn in 
group B (20.6%), all because of protracted treatment-related 
Figure 1. Flow chart of patients, reasons for treatment discontinuation and outcome of treatment. 
tAble 2. Cumulative results of the study
Patients 
oAc-14 plus S. boulardii
(group A)
oAc-14 alone
(group b) P
n 36 34 n.s.
Completed treatment, n (%) 33 (91.7%) 27 (79.4%) 0.182
Withdrawals, n (%)  
voluntary 
diarrhea 
3 (8.3%)
2 (5.6%)
1 (2.8%)
7 (20.6%)
0
7 (20.6%)
n.s.
0.026
Eradication of H. pylori  
[n, (%) ITT analysis]
30/36 
(83.4%)
20/34
(58.8%)
0.034
Eradication of H. pylori  
[n, (%), PP analysis]
30/33
(90.9%) 
20/27 
(74.1%)
0.097
OAC-14: Omeprazole, Amoxicillin, and Clarithromycin anti-H. pylori classical triple therapy for 14 days, ITT: Intention-To-Treat analysis, PP: Per 
Protocol analysis, n.s.: not significant
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CTT.24, 26-29 A meta-analysis of 5 randomized controlled studies 
with various end-points involving 1307 subjects (1217 adults 
and 90 children) who were treated with CTT and S. boulardii 
vs placebo or no intervention has been published recently. 
Eradication rates of H. pylori infection was assessed in 4 of 5 
trials involving 915 patients (the end-point of the 5th trial was 
only prevention of diarrhea and eradication rates were not 
reported); the combination of S. boulardii and CTT increased 
significantly the eradication rates of H. pylori compared to 
placebo or no intervention [relative risk (RR) 1.13, 95% CI 
1.05-1.21, with an absolute gain in eradication rates of 9% and a 
number needed to treat (NNT) of 11]. Occurrence of diarrhea 
was an end-point in 4 of 5 trials in the meta-analysis involving 
1215 patients; the combined treatment reduced significantly the 
risk for developing diarrhea (RR 0.47, 95% CI 0.32-0.69, with 
an absolute risk reduction (ARR) of 6.6% and a NNT of 16). 
Finally, the RR for developing any adverse event was tested 
in all 5 trials involving 1305/1307 patients (two patients who 
did not complete the anti-H. pylori treatment were excluded). 
The incidence of diarrhea was reduced significantly by the 
combined treatment (RR 0.46, 95% CI 0.3-0.7, with an ARR 
of 11.4% and a NNT of 11) but when adverse events other 
than diarrhea were analyzed there was no statistical difference 
between patients on S. boulardii vs. no intervention/placebo.30 
These results support the important role of S. boulardii as an 
adjunct to CCT to prevent diarrhea and increase compliance 
of patients with anti-H. pylori regimens. 
Our study is in accordance with the results of this meta-
analysis30 and some previous reports depending on the popu-
lation studied, type and duration of therapy, and whether 
analysis of results was performed on an intention-to-treat or 
per protocol.24,26-29 For instance, Song et a26 found significantly 
higher reported eradication rates for the S. boulardii group 
compared with a control group (80% vs. 71,6%, respec-
tively, ITT analysis, P=0,03). Chindoruk et al27 treated 124 
patients with H. pylori infection with a 14-day triple therapy 
(clarithromycin 500 mg b.i.d., amoxicillin 1000 mg b.i.d., 
and lansoprazole 30 mg b.i.d.) plus S. boulardii or placebo. 
Although H. pylori eradication rates were numerically but 
not statistically higher in the treatment group [44/62 (71%) 
vs. 37/62 (59.7%), PP analysis] the incidence of diarrhea was 
statistically lower in the S. boulardii group [9 (14.5%) vs.19 
(30.6%), respectively, P<0.05]. Cremonini et al28 using a 7-day 
rabeprazole, tinidazole and amoxycilin H. pylori eradication 
regimen in association with 3 different probiotic strains or 
placebo showed a trend towards better eradication rate with 
the probiotics (81% vs 76%, PP analysis) but a significantly 
higher reduction in the incidence of diarrhea. Also, in the study 
of Hurduc et al29 in infected children, the H. pylori eradication 
rate in controls was 80.9% vs. 93.3% in the S. boulardii group 
(PP analysis, P=0.750). However, the incidence of side effects 
was reduced in the S. boulardii group (8.3% vs. 30.9% in the 
control, P=0.047) leading to the conclusion that the addition 
diarrhea. C. difficile toxin A was isolated in the stools of two 
of 7 patients in group B who were withdrawn for diarrhea and 
were treated accordingly (Table 2). Thus, although by ITT 
analysis there was no significant difference between groups 
A and B in the proportion of patients completing the study 
(91.7% vs 79.4% for groups A and B, respectively, P=0.182, 
95% CI 6.7% to 39.25%) withdrawals for treatment-related 
diarrhea were significantly fewer in patients receiving adjunc-
tive probiotic therapy [1 of 36 (2.8%) cases (group A) vs 7 
of 34 (20.6%) cases (group B), respectively, 95% CI 3.3% to 
32.7%, P=0.026] (Table 2). The absolute risk reduction for 
diarrhea in patients receiving the combination therapy of 
OAC-14 and S. boulardii therapy over patients treated with 
OAC-14 alone was 17.8%.
There were no significant differences in eradication rates 
between patients with peptic ulcer disease or functional dys-
pepsia both within and between treatment groups (data not 
shown). None of the patients developed systemic S. boulardii 
infection. 
d i s c u s s i o n 
Classic triple therapy (CTT) consisting of the combination 
of a PPI and two antibiotics, clarithromycin and amoxililin, is 
still considered the treatment of choice for eradication of H. 
pylori infection. However, resistance to clarithromycin and 
poor adherence may undermine the efficacy of treatment. 
Antibiotic- and PPI-related related diarrhea is the predomi-
nant cause for premature cessation of treatment that results 
in failure to eradicate H. pylori and development of H. pylori 
strains resistant to antibiotics. Preventing adverse events, 
and especially diarrhea, is not only an attractive but also a 
very cost-effective strategy to enhance adherence resulting 
in completeness of treatment and higher eradication rates. 
Various lactobacilli can inhibit or even eliminate H. pylori 
in vitro10,11 and in vivo either directly or by secreted metabolic 
products, especially lactic acid, and may also increase the effi-
cacy of antibiotics.12-21 S. boulardii induces morphologic changes 
that are consistent with cellular damage in H. pylori cell lines23 
and reduces H. pylori colonization of infected children.24 S. 
boulardii has also been tested with varied degrees of clinical 
efficacy in several types of acute diarrhea including antibiotic-
associated diarrhea, C. difficile infection, acute adult diarrhea, 
enteral nutrition-related diarrhea, and traveler’s diarrhea.22 In 
theory, therefore, S. boulardii probiotics could prevent and/or 
counterbalance the untoward effects of antibiotics and/or PPIs 
on the intestinal microflora allowing patients to complete a 14-
day CTT but may also exert synergistic affects with antibiotics 
by their potential direct anti-H. pylori action. Indeed, there are 
five studies in the literature in adults and pediatric population 
that have suggested that S. boulardii increases the eradication 
rates of H. pylori and prevents adverse events related to the 
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of S. boulardii to the standard eradication treatment conferred 
a 12% non non significant enhanced therapeutic benefit on H. 
pylori eradication and reduced significantly the incidence of 
side effects. In our study, eradication rates were significant on 
ITT analysis but felt marginal significance in the PP analysis; 
however, the incidence of diarrhea was significantly reduced 
irrespective of the analysis used. As in all these studies the 
concomitant administration of S. boulardii with CTT against 
H. pylori led to statistically or numerically higher eradication 
rates and to statistical reduction of diarrhea it is not surprising 
that the results of the Szajewska et al30 meta-analysis justified 
the use of S. boulardii as adjunctive therapy of CTT for better 
tolerance of therapy resulting in increased eradication rates 
of the infection. 
Although a direct effect of S. boulardii on anti-H. pylori 
cannot be excluded, this study was not adequately powered to 
reveal any synergistic effect(s) of S. boulardii and CTT. It is, 
therefore, likely that prevention of treatment-related diarrhea 
was the leading mechanism underlying the higher efficacy of 
the combined treatment. Indeed, the combined treatment 
was tolerated very well by all except one patient. The other 
two patients with peptic ulcer disease stopped prematurely 
the combined treatment not because they developed adverse 
events but because they felt very well after 10 days of treatment 
(Figure 1, Table 2). In fact, both patients were tested negative 
by a 13C-UBT outside the context of this clinical trial 6 and 8 
months later, respectively, after the cessation of treatment.
A limitation of our study was the lack of a placebo con-
trolled arm that would ensure an entirely blind study for all 
investigators and the rather small number of patients to assess 
any long-term effects of combination therapy vs. OAC-14. 
However, this is at least in part counterbalanced by the heavy 
involvement of a single unblinded investigator who was respon-
sible for many activities in the trial that could lead to potential 
violation of the results. None of the other study personnel was 
aware of any treatment intervention. In addition, although 
this study was not double-blind, patients were unaware that 
there was another study arm employing a different treatment. 
Therefore, there was no ground for potential bias in subjects 
of stratum B reporting diarrhea or any other symptoms as a 
result of knowledge that another patient group were receiving 
S. boulardii preparations 
In conclusion, this study adds evidence to recommend 
the concomitant use of S. boulardii with OAC-14, a CTT, for 
eradicating H. pylori in order to reduce treatment-related diar-
rhea and enhance compliance with treatment which may lead 
to higher rates of eradication of this pathogen. 
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